Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301270 | 0.81 | KDM4E (0.57) | CSNK2A1KDM4EALDH1A1HPGDGLA | |
| SCHEMBL4224441 | 0.80 | USP1 (0.47) | — | |
| SCHEMBL300889 | 0.80 | KDM4E (0.53) | CSNK2A1KDM4EALDH1A1HPGDGLA | |
| SCHEMBL300821 | 0.79 | PIK3CD (0.65) | CSNK2A1KDM4EALDH1A1HPGDGLA | |
| SCHEMBL29793901 | 0.79 | PIK3CD (0.65) | CSNK2A1KDM4EALDH1A1HPGDGLA | |
| SCHEMBL300864 | 0.78 | KDM4E (0.53) | CSNK2A1KDM4EALDH1A1HPGDGLA | |
| SCHEMBL301255 | 0.77 | CSNK2A1 (0.51) | CSNK2A1KDM4EALDH1A1HPGDGLA | |
| SCHEMBL300956 | 0.75 | KDM4E (0.50) | CSNK2A1KDM4EALDH1A1HPGDGLA | |
| SCHEMBL301263 | 0.74 | KDM4E (0.49) | CSNK2A1KDM4EALDH1A1HPGDGLA | |
| SCHEMBL301283 | 0.72 | KDM4E (0.81) | CSNK2A1KDM4EALDH1A1HPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | claimed |
| CN-107976546-B | Inhibition of phosphorylation of TOR kinase inhibitory Activity markers PRAS40, GSK 3-beta, or P70S6K1 | 西格诺药品有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-110721186-A | Treatment of prostate cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-107157990-B | Treatment of cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-2908814-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2909627-A2 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | Signal Pharmaceuticals, LLC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2825170-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825171-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825168-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825169-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013138560-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013126636-A1 | METHODS FOR TREATING NON- SMALL CELL LUNG CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013059396-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013019927-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-2531194-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2012-12-12 | — | — | EP | disclosed |
| CN-102821767-A | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARM LLC | 2012-12-12 | — | — | CN | disclosed |
| WO-2011097333-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-08-11 | — | — | WO | disclosed |
| CN-101679432-A | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2010-03-24 | — | — | CN | disclosed |
| EP-2078018-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |